Back to top

Analyst Blog

SurModics Inc.’s (SRDX - Analyst Report) third quarter fiscal 2012 earnings from continued operations (excluding special items) of 17 cents per share were above the Zacks Consensus Estimate of 13 cents. The company earned 12 cents per share on an adjusted basis in the year-ago quarter. Higher year-over-year earnings were primarily attributable to increased adjusted revenues.

Adjusted revenues climbed 17.5% year over year to $13.7 million in the reported quarter, edging past the Zacks Consensus Estimate of $13 million. Revenues on a reported basis (including special items) were up 7.4% to approximately $14 million in the third quarter of fiscal 2012.

Revenues at SurModics climbed up due to increased sales from vitro diagnostics and hydrophilic coatings. However, this was partly offset by a decline in royalty revenues from Johnson & Johnson (JNJ - Analyst Report) pertaining to Cypher and Cypher Select Plus drug eluting stents. Johnson & Johnson stopped manufacturing these products from the end of calendar year 2011.

For the reported quarter, royalties and license fees accounted for approximately 50.2% of total adjusted revenue with product sales and research & development accounting for 41.7% and 8.1%, respectively.

Following the November 2011 sale of the assets of its Pharmaceuticals division to Germany’s Evonik Industries AG, SurModics currently operates through two business units: Medical Devices and In Vitro Diagnostics.

SurModics’ reported revenues from the Medical Devices segment were approximately $10.3 million, up 7.4%. Growth was attributable to an increase in sales of hydrophilic coatings and newly launched customer products.

Reported revenues from the In Vitro Diagnostics unit increased 7.3% to $3.7 million.

In addition to announcing financial results, SurModics stated that a $55 million share buyback program has been authorized by its Board of Directors. We believe that the buyback program highlights the company’s commitment to create value for shareholders.

Our Recommendation

We currently have a Neutral recommendation on SurModics. The stock carries a Zacks #3 Rank (short-term Hold rating).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%